By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial
Investing

AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial

News Room
Last updated: 2023/05/18 at 1:05 AM
By News Room
Share
1 Min Read
SHARE
By Christian Moess Laursen

AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong improvement for patients with lung cancer

The Anglo-Swedish pharmaceutical company said the FLAURA2 Phase 3 trial was for progression-free survival–the length of time a patient lives with a disease without it getting worse–for patients with epidermal growth factor receptor-mutated, non-small cell lung cancer.

For the moment, the overall survival data–the length of time from the start of diagnosis or treatment that the patient is still alive–were still immature and will be formally assessed at a subsequent analysis, AstraZeneca said.

“These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing,” Executive Vice President of the company’s Oncology R&D Susan Galbraith said.

Write to Christian Moess Laursen at christian.moess@wsj.com


Read the full article here

News Room May 18, 2023 May 18, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
US-China trade war is pushing Asian nations to pick sides, ministers warn

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Merz backs Nord Stream ban to prevent US and Russia restarting gas link

Stay informed with free updatesSimply sign up to the German politics myFT…

How Israel tries to shield its diplomats from attack

Since the founding of the Israeli state, staff at its embassies and…

Apple set to expand India supply chain through $1.5bn Foxconn plant

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Supreme Court signals it could shield Federal Reserve from Donald Trump

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?